ROVI obtains second place in a global sustainability rating

ROVI has obtained second place among 360 international pharmaceutical companies in the sustainability rating drawn up by Sustainalytics, a global leader in the evaluation of the Corporate Social Responsibility and Corporate Governance


ROVI participated voluntarily in this rating, which measures the sustainability of companies based on criteria such as corporate governance, business ethics, product management, bribery and corruption and human capital, among others. Thus, the ESG (Environmental, Social and Governance) rating is calculated and furnishes the basis for the company ratings.

In this rating, ROVI obtained the second best rating in the pharmaceutical company category and the 30th of a total of 750 companies in the sector, which includes biotechnology companies and pharmaceutical and health equipment laboratories.

We are proud to see that the management of ROVI, a day-to-day reflection of the company’s values, has received such a high sustainability rating.

No votes yet
 
Relacionados
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
  Los ingresos operativos aumentaron un 23%, hasta alcanzar los 101,0 millones de euros en el primer trimestre de 2020, como...
8 min
13/05/2020
ROVI signs a co-operation agreement for a clinical trial to study the efficacy and safety of bemiparin in patients hospitalised with pneumonia caused by COVID-19
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) ha firmado un convenio de colaboración con la Fundación de Investigación HM Hospitales para...
2 min
14/04/2020
ROVI informs on the impact of Covid 19 on the company’s activities
Laboratorios Farmacéuticos ROVI, S.A. (ROVI), informa de que desde el inicio de la propagación del Covid-19, la compañía está ejecutando...
7 min
02/04/2020